Cart 0 Items
Total $ 0.00

24hr Drugstore Chemist & Pharmacy

Skin & Hair Care
    Home > Skin & Hair Care > Betnovate (Betamethasone valerate cream)

Betnovate (Betamethasone valerate cream)
J581 Betnovate (Betamethasone valerate cream) GSK 1 x 20gm tube 0.1% $2.45
J370 Betamethasone Generic 10 tabs 0.5 mg $1.68
Price is per pack & not per tab.. eg: if pack size is 10 tabs & price is $2.75 then for 100 tabs the price would be $27.50

Betnovate Cream

Betamethasone Valerate BP 0.122% W/W


Aqueous Cream


Therapeutic indications
Betamethasone valerate is an active topical corticosteroid which produces a rapid response in those inflammatory dermatoses that are normally responsive to topical corticosteroid therapy, and is often effective in the less responsive conditions such as psoriasis.

Betnovate preparations are indicated for the treatment of eczema in children and adults, including atopic and discoid eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis); neurodermatoses, including lichen simplex, lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus and they may be used as an adjunct to systemic steroid therapy in generalised erythroderma.

Posology and method of administration
A small quantity of Betnovate should be applied gently to the affected area two or three times daily until improvement occurs. It may then be possible to maintain improvement by applying once a day, or even less often, or by using the appropriate ready-diluted (1 in 4) preparation Betnovate R.D. If no improvement is seen within two to four weeks, reassessment of the diagnosis, or referral, may be necessary.

Betnovate and Betnovate R.D. creams are especially appropriate for dry, lichenified or scaly lesions, but this is not invariably so.

In the more recent resistant lesions, such as the thickened plaques of psoriasis on elbows and knees, the effect of Betnovate can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response in such lesions; thereafter improvement can usually be maintained by regular application without occlusion.

Courses should be limited to five days. Occlusion should not be used.

For topical administration.

Rosacea, acne and perioral dermatitis. Primary cutaneous viral infections (e.g. herpes simplex, chickenpox). Hypersensitivity to any component of the preparation.

The use of Betnovate skin preparations is not indicated in the treatment of primarily infected skin lesions caused by infections with fungi (e.g. candidiasis, tinea); or bacteria (e.g. impetigo); primary or secondary infections due to yeast; peri-anal and genital pruritus; dermatoses in children under 1 year of age, including dermatitis and napkin eruptions.

Special warnings and precautions for use
Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression, with or without clinical features of Cushing's syndrome, can occur even without occlusion. In this situation, topical steroids should be discontinued gradually under medical supervision because of the risk of adrenal insufficiency (see Undesirable Effects and Overdose).

The face, more than other areas of the body, may exhibit atrophic changes after prolonged treatment with potent topical corticosteroids. This must be borne in mind when treating such conditions as psoriasis, discoid lupus erythematosus and severe eczema. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as glaucoma might result.

If used in childhood, or on the face, courses should be limited to five days and occlusion should not be used.

Topical corticosteroids may be hazardous in psoriasis for a number of reasons including rebound relapses, development of tolerance, risk of generalised pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin. If used in psoriasis careful patient supervision is important.

Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected. Any spread of infection requires withdrawal of topical corticosteroid therapy and systemic administration of antimicrobial agents. Bacterial infection is encouraged by the warm, moist conditions induced by occlusive dressings, and so the skin should be cleansed before a fresh dressing is applied.

Further Information
The least potent corticosteroid which will control the disease should be selected. None of these preparations contain lanolin. Betnovate Cream and Ointment and the corresponding RD preparations do not contain parabens. Betnovate Lotion contains parabens.

Interaction with other medicinal products and other forms of interaction
None known.

Pregnancy and lactation
There is inadequate evidence of safety in human pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There may therefore be a very small risk of such effects in the human foetus.

Effects on ability to drive and use machines
None known

Undesirable effects
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000) and very rare (<1/10,000) including isolated reports. Very common, common and uncommon events were generally determined from clinical trial data. The background rates in placebo and comparator groups were not taken into account when assigning frequency categories to adverse events derived from clinical trial data, since these rates were generally comparable to those in the active treatment group. Rare and very rare events were generally determined from spontaneous data.

Immune system disorders
Very rare: Hypersensitivity.

If signs of hypersensitivity appear, application should stop immediately.

Endocrine disorders
Very rare: Features of Cushing's syndrome

As with other topical corticosteroids, prolonged use of large amounts or treatment of extensive areas can result in sufficient systemic absorption to produce suppression of the HPA axis and the clinical features of Cushing's syndrome (see Special Warnings and Precautions for use). These effects are more likely to occur in infants and children, and if occlusive dressings are used. In infants the napkin may act as an occlusive dressing.

Skin and subcutaneous tissue disorders
Common: Local skin burning and pruritus.

Very rare: Local atrophic changes in the skin such as thinning, striae and dilatation of the superficial blood vessels may be caused by prolonged and intensive treatment with highly active corticosteroid preparations, particularly when occlusive dressings are used or when skin folds are involved.

Pigmentation changes, hypertrichosis, allergic contact dermatitis, exacerbation of symptoms, pustular psoriasis (due to treatment of psoriasis with corticosteroids or its withdrawal: see Special Warnings and Precautions for use)



Ordering at NPD is very easy. From the range of medications above please select the pack size and strength and then click Add to cart. In the cart you will be able to select the quantity you require. Simply complete all the necessary information on the checkout forms as they appear.. Your order will be checked through by a qualified pharmacist and will be dispatched promptly in an unmarked discreet package as soon as we have verified your credit card details with our payment processor. All orders are received via a secure server, protected by 128bit encryption, to ensure that your details are kept confidential ..Save on prescription drugs, medications and pills inhouse from our online Canada pharmacy.

Save on cancer, HIV, ultram, diabetes, allergy, pain relief and antibiotics drugs